MedTrace Logo

Rectal Cancer Staging Using Whole Body MR-PET

NCT02651701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2019-12-12

No results posted yet for this study

Summary

The purpose of this study is to measure the diagnostic performance of whole body (WB) MR-PET for staging rectal cancer, compared with current standard of care (chest/abdominopelvic CT and rectal MRI) to investigate clinical feasibility of WB MR-PET as a one-stop preoperative imaging modality in patients with rectal cancer.

Conditions

Interventions

PROCEDURE

MR-PET

whole body MR-PET with dedicated liver+rectal protocol

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Hee Yoon, MD · Seoul National University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-08-08
Completion
2019-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02651701 on ClinicalTrials.gov